PTC Therapeutics, Inc. (PTCT)

Price$70.97

Value ScoreC

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-25.39%

Price vs S&P 500 (4W)-3.68%

VGM Score50.57

Market Capitalization$5.89B

P/E Ratio (Annual)8.62x

All Metrics

P/CF (Annual)8.28x

Book Value / Share (Quarterly)$237.80

P/TBV (Annual)14.29x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)128.31%

Cash Flow / Share (Quarterly)$7.75

Price vs S&P 500 (YTD)-14.73%

Gross Margin (TTM)32.64%

Net Profit Margin (TTM)0.89%

EPS (TTM)$4.49

10-Day Avg Trading Volume1.09M

EPS Excl Extra (TTM)$4.49

Revenue Growth (5Y)135.44%

EPS (Annual)$7.73

ROI (Annual)-0.77%

Gross Margin (Annual)97.28%

Net Profit Margin (5Y Avg)-9.01%

Cash / Share (Quarterly)$22.83

P/E Basic Excl Extra (TTM)796.93x

Revenue Growth QoQ (YoY)-76.83%

P/E Normalized (Annual)8.62x

ROA (Last FY)23.55%

Revenue Growth TTM (YoY)-53.34%

EBITD / Share (TTM)$5.54

ROE (5Y Avg)-7518.48%

Operating Margin (TTM)8.87%

Cash Flow / Share (Annual)$8.62

P/B Ratio10.97x

P/B Ratio (Quarterly)9.14x

Net Income / Employee (Annual)$688,800

EV / Revenue (TTM)9.28x

Net Interest Coverage (TTM)5.26x

ROA (TTM)0.33%

EV / EBITDA (TTM)62.07x

EPS Incl Extra (Annual)$7.73

Current Ratio (Annual)2.35x

Quick Ratio (Quarterly)2.29x

3-Month Avg Trading Volume1.21M

52-Week Price Return37.19%

EV / Free Cash Flow (Annual)10.93x

P/E Incl Extra (TTM)796.93x

Revenue / Employee (TTM)$834,600

Tangible BV / Share (Quarterly)$237.80

P/S Ratio (Annual)3.40x

Asset Turnover (Annual)0.60x

52-Week High$87.50

Operating Margin (5Y Avg)3.91%

EPS Excl Extra (Annual)$7.73

CapEx CAGR (5Y)-38.20%

26-Week Price Return-17.47%

Quick Ratio (Annual)2.20x

13-Week Price Return12.06%

Total Debt / Equity (Annual)0.51x

Current Ratio (Quarterly)2.44x

Enterprise Value$7.67B

Revenue / Share Growth (5Y)13.07%

Asset Turnover (TTM)0.37x

Book Value / Share Growth (5Y)62.78%

Revenue / Employee (Annual)$1,746,400

Inventory Turnover (Annual)0.91x

Pretax Margin (Annual)40.25%

Cash / Share (Annual)$23.88

3-Month Return Std Dev51.56%

Gross Margin (5Y Avg)64.12%

Net Income / Employee (TTM)$7,500

EBITDA CAGR (5Y)78.03%

ROE (Last FY)-1.17%

Net Interest Coverage (Annual)1.47x

EPS Basic Excl Extra (Annual)$7.73

P/FCF (TTM)2.51x

Receivables Turnover (TTM)3.84x

EV / Free Cash Flow (TTM)11.95x

Total Debt / Equity (Quarterly)0.03x

EPS Incl Extra (TTM)$4.49

Receivables Turnover (Annual)10.18x

ROI (TTM)0.13%

P/S Ratio (TTM)7.12x

Pretax Margin (5Y Avg)-6.60%

Revenue / Share (Annual)$19.60

Tangible BV / Share (Annual)$109.71

Forward P/E78.57x

Price vs S&P 500 (52W)12.83%

P/E Ratio (TTM)796.93x

EPS Growth TTM (YoY)-30.96%

Year-to-Date Return-6.57%

5-Day Price Return-3.83%

EPS Normalized (Annual)$7.73

ROA (5Y Avg)-12.86%

Net Profit Margin (Annual)39.44%

Month-to-Date Return-3.90%

Cash Flow / Share (TTM)$-6.03

EBITD / Share (Annual)$10.10

EPS Growth (3Y)-2.88%

Operating Margin (Annual)50.09%

LT Debt / Equity (Annual)0.51x

P/CF (TTM)9.03x

ROI (5Y Avg)-25.45%

P/E Excl Extra (TTM)796.93x

LT Debt / Equity (Quarterly)0.03x

EPS Basic Excl Extra (TTM)$4.49

P/TBV (Quarterly)9.14x

P/B Ratio (Annual)14.29x

Inventory Turnover (TTM)2.43x

Pretax Margin (TTM)2.84%

Book Value / Share (Annual)$109.72

Price vs S&P 500 (13W)3.81%

Beta0.58x

P/FCF (Annual)8.38x

Revenue / Share (TTM)$10.02

ROE (TTM)0.13%

52-Week Low$43.17

vGradeC

gGradeC

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.03est. -0.48

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.95

3.81

3.82

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
PTCTPTC Therapeutics, Inc.	C	C	B	$70.97
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

PTC Therapeutics develops and commercializes medicines for rare genetic and metabolic disorders, with a focus on neurology. The company markets several FDA-approved therapies and maintains a pipeline of clinical and preclinical candidates for pediatric and adult patients. Its diversified portfolio addresses significant unmet needs in rare disease treatment.